Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sirion Therapeutics Inc.

This article was originally published in Start Up

Executive Summary

Fenretinide, Sirion Therapeutics' lead candidate, targets the pathway by which Vitamin A gets into the eye and becomes part of A2E, the protein complex that scientists consider a bad actor in AMD. Intermediate analysis of fenretinide Phase II data showed that patients taking the compound had slower growth of lesions than those given placebo, and that trend increased over time.

You may also be interested in...



Acucela Strikes Third Ophthalmology Deal With Otsuka For Glaucoma Drug

Seattle-based ophthalmology specialist Acucela has struck its third partnership with Japanese pharma Otsuka Pharmaceutical Co., this time to collaborate on development of a preclinical glaucoma treatment

Acucela Strikes Third Ophthalmology Deal With Otsuka For Glaucoma Drug

Seattle-based ophthalmology specialist Acucela has struck its third partnership with Japanese pharma Otsuka Pharmaceutical Co., this time to collaborate on development of a preclinical glaucoma treatment

Acucela Strikes Third Ophthalmology Deal With Otsuka For Glaucoma Drug

Building on deals in AMD and dry eye, the U.S. eye care startup will conduct trials on a novel glaucoma treatment, with an option to co-promote.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM006922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel